DOT or SAT for Rifampicin-resistant tuberculosis? A non-randomized comparison in a high HIV-prevalence setting

• Erika Mohr ,

  * E-mail: msfocb-khayelitsha-drtb-epi@burssels.msf.org

  Affiliation Médecins Sans Frontières (MSF), Khayelitsha, South Africa

  http://orcid.org/0000-0001-5269-6503

  ⨯
• Johnny Daniels,

  Affiliation Médecins Sans Frontières (MSF), Khayelitsha, South Africa

  ⨯
• Busisiwe Beko,

  Affiliation Médecins Sans Frontières (MSF), Khayelitsha, South Africa

  ⨯
• Petros Isaakidis,

  Affiliation Médecins Sans Frontières (MSF), South African Medical Unit, Cape Town, South Africa

  ⨯
• Vivian Cox,

  Affiliation University of Cape Town (UCT), Center for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, Cape Town, South Africa

  ⨯
• Sarah Jane Steele,

  Affiliation Médecins Sans Frontières (MSF), Cape Town, South Africa

  ⨯
• Odelia Muller,

  Affiliation Médecins Sans Frontières (MSF), Khayelitsha, South Africa

  ⨯
• Leigh Snyman,

  Affiliation Médecins Sans Frontières (MSF), Khayelitsha, South Africa

  ⨯
• Virginia De Azevedo,

  Affiliation City of Cape Town Health Department, Cape Town, South Africa

  ⨯
• Amir Shroufi,

  Affiliation Médecins Sans Frontières (MSF), Cape Town, South Africa

  ⨯
• Laura Trivino Duran,

  Affiliation Médecins Sans Frontières (MSF), Khayelitsha, South Africa

  ⨯
• Jennifer Hughes

  Affiliation Médecins Sans Frontières (MSF), Khayelitsha, South Africa

  ⨯